Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hamps BioBOM:544312 -2.17%12 EBITDA Margin % is 3.22% as of Mar. 2026, which is 77% below its 10-year median of 13.80. GuruFocus rates BOM:544312 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Hamps Bio ranks worse than 67.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Hamps Bio's EBITDA for the
six
months ended in Mar. 2026 was ₹1.44 Mil. Hamps Bio's Revenue for the
six
months ended in Mar. 2026 was ₹44.83 Mil. Therefore, Hamps Bio's EBITDA margin for the quarter that ended in Mar. 2026 was 3.22%.
Hamps Bio (BOM:544312) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hamps Bio EBITDA Margin % Related Terms
Hamps Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Hamps Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Hamps Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hamps Bio EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Hamps Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hamps Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hamps Bio (BOM:544312) has a EBITDA Margin % of 3.22% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hamps Bio and its competitors. This is 77% below median its historical median of 13.80. Over the past decade, Hamps Bio's EBITDA Margin % has ranged from 4.32 to 20.15. According to the industry distribution chart, Hamps Bio ranks #446 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 67.2%.
Is Hamps Bio's EBITDA Margin % too high?
Hamps Bio's current EBITDA Margin % of 3.22% is 77% below median its 10-year median of 13.80. Over the past 10 years, this metric has ranged from a low of 4.32 to a high of 20.15. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Hamps Bio's value of 3.22% is 68.5% below this industry median. Based on the distribution chart, Hamps Bio ranks #446 out of 664 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Hamps Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Hamps Bio's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Hamps Bio ranks #446 out of 664 companies for EBITDA Margin %. This places Hamps Bio in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Hamps Bio's value of 3.22% is 68.5% below this benchmark. Historically, Hamps Bio's own EBITDA Margin % has ranged from 4.32 to 20.15 over the past decade. While the company's 10-year median is 13.80 vs. the industry median of 10.21, Hamps Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hamps Bio's current EBITDA Margin % of 3.22% is 68.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hamps Bio and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hamps Bio's current EBITDA Margin % is 3.22%, which is 77% below median its own 10-year median of 13.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamps Bio stock overvalued right now?
Hamps Bio (BOM:544312) has a current EBITDA Margin % of 3.22%. The current EBITDA Margin % is 3.22%, which is 77% below median its 10-year median of 13.80 and 68.5% below the Healthcare Providers & Services industry median of 10.21. Hamps Bio's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hamps Bio (BOM:544312), the current EBITDA Margin % is 3.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hamps Bio Ltd is engaged in the ethical marketing and distribution of pharmaceutical formulation products. Its product include tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products such as fruits, vegetables, herbs and flowers. The company segment includes Manufacturing, trading and distribution of Pharmaceutical formulation products and Manufacturing of Freeze dried and frozen products like fruits, vegetables, herbs, flowers, etc. Key revenue is generated from Medicine Products.
12GF Score
Get the complete analysis for BOM:544312
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544312 has been successfully added to your 
